AMW GmbH Welcomed Bavarian State Secretary for Economic Affairs Gotthardt at its Warngau Headquarters
Warngau, Germany, August 5, 2026
AMW GmbH, a specialty pharmaceutical company focused on biodegradable controlled-release drug delivery systems, today reported on the visit by Bavarian State Secretary for Economic Affairs Tobias Gotthardt to its headquarters in Warngau, south of Munich.
Company representatives of AMW, including the two managing directors Philipp Karbach and Dr. Joerg Serafimov, informed Mr. Gotthardt about innovative approaches to drug development during a tour of the site. “The pharmaceutical industry is a key sector with a high level of innovation,” commented Tobias Gotthardt, State Secretary at the Bavarian Ministry of Economic Affairs, Regional Development, and Energy. “Companies like AMW demonstrate that competitiveness arises where highly skilled employees, expertise, and entrepreneurial spirit come together. Especially in times of global change, we need strong, regionally grounded companies that, at the same time, are internationally competitive.”
“We were very pleased to have the opportunity to welcome State Secretary Gotthardt to AMW,” added Philipp Karbach, CEO and shareholder of AMW GmbH. “As a fast-growing employer in the region, we have nearly doubled the number of high-skilled jobs over the past ten years. We are firmly committed to our location in Warngau, with detailed plans for expansion and additional production capacity. At the same time, as an internationally active specialty pharmaceutical company, we depend on optimal conditions to ensure that we can continue to operate sustainably with cutting-edge technology in the future. Therefore, ongoing dialogue between the private sector and politics is a decisive factor for success in securing Bavaria’s competitiveness.”
###
About AMW GmbH:
AMW is a specialty pharmaceutical company focused on biodegradable implants, providing patients and partners access to value-added medicines for improved adherence and cost-effective therapies. The Company covers the entire value chain, from (co-)development to manufacturing and international commercialization.
AMW has three pharmaceutical products on the market: implants releasing goserelin or leuprorelin respectively, which are distributed in numerous markets via direct sales and out-licensing. In Germany, leuprorelin is marketed as Leugon® by AMW’s fully owned subsidiary Endomedica GmbH. Based on its unparalleled expertise in formulation development, the Company collaborates with pharma and biotech partners worldwide to develop and manufacture high-quality products and life-cycle solutions.
AMW is based in Warngau, south of Munich, Germany.
For further information, please contact:
AMW GmbH
Eva Hoffmann
Phone.: +49 8024 470999-0
Email: